Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Tango Therapeutics | 2026 | Post-IPO Equity | Undisclosed | Cambridge |
| Jade Biosciences | 2026 | Post-IPO Equity | Undisclosed | Waltham |
| ALX Oncology | 2026 | Post-IPO Debt | Undisclosed | San Francisco |
| Lycia Therapeutics | 2026 | Series D | Undisclosed | South San Francisco |
| Helus Pharma | 2026 | Post-IPO Equity | Undisclosed | Toronto |
| Definium Therapeutics | 2026 | Post-IPO Equity | Undisclosed | New York |
| Triveni Bio | 2026 | Series C | $115.0M | Watertown |
| Enliven Therapeutics | 2026 | Post-IPO Equity | Undisclosed | Boulder |
| Parabilis Medicines | 2026 | Post-IPO Equity | $305.0M | Cambridge |
| Shattuck Labs | 2026 | Post-IPO Equity | Undisclosed | Austin |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Tango Therapeutics | Post-IPO Equity | Undisclosed | Cambridge, United States |
| 2 | Jade Biosciences | Post-IPO Equity | Undisclosed | Waltham, United States |
| 3 | ALX Oncology | Post-IPO Debt | Undisclosed | San Francisco, United States |
| 4 | Lycia Therapeutics | Series D | Undisclosed | South San Francisco, United States |
| 5 | Helus Pharma | Post-IPO Equity | Undisclosed | Toronto, Canada |
| 6 | Definium Therapeutics | Post-IPO Equity | Undisclosed | New York, United States |
| 7 | Triveni Bio | Series C | $115.0M | Watertown, United States |
| 8 | Enliven Therapeutics | Post-IPO Equity | Undisclosed | Boulder, United States |
| 9 | Parabilis Medicines | Post-IPO Equity | $305.0M | Cambridge, United States |
| 10 | Shattuck Labs | Post-IPO Equity | Undisclosed | Austin, United States |
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.
Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.
Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.
Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.
Ocugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes.
Wallbox is a technology company that provides electric vehicle charging and energy management solutions.
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Calyxo is a medical device company that improves kidney stone treatment through specialized urology technologies.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.
Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
Galvanize is a biomedical platform company that provides therapeutic products and services to deliver healthcare solutions.
Bambusa Therapeutics operates as biotechnology company.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Parse Biosciences is a biotechnology startup company that develops single-cell sequencing kit solutions for researchers.
TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
Janus Henderson Investors has invested in 121 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 22 different industry categories.
Among tracked funding rounds, Kailera Therapeutics received $600.0M in a Series B round. Janus Henderson Investors's total known invested capital is $12.5B.
Janus Henderson Investors's average investment size is $129.0M across its portfolio of 121 companies.
Recent Janus Henderson Investors portfolio additions include Tango Therapeutics, Jade Biosciences, ALX Oncology, Lycia Therapeutics, Helus Pharma. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors